TAK-875 Mitigates β-Cell Lipotoxicity-Induced Metaflammation Damage through Inhibiting the TLR4-NF-κB Pathway

Area of Science:

• Metabolic inflammation
• Endocrinology
• Cellular biology

Background:

• Metabolic inflammatory damage, driven by Toll-like receptor 4 (TLR4) signaling, is a key factor in lipotoxicity-induced beta-cell damage.
• Understanding the role of G protein-coupled receptor 4 (GPR40) in mitigating this damage is crucial for metabolic disease research.

Purpose of the Study:

• To investigate if GPR40 agonists can ameliorate beta-cell damage caused by lipotoxicity.
• To determine if this protective effect involves the inhibition of the TLR4-NF-κB pathway.

Main Methods:

• Utilized in vitro cell cultures and in vivo obese Sprague-Dawley (SD) rat models, including TLR4 knockout (KO) rats.
• Administered TAK-875, a GPR40 agonist, and assessed beta-cell apoptosis, insulin secretion, and expression of TLR4 and NF-κB.
• Evaluated effects on body weight, inflammatory factors, and islet cell apoptosis and distribution in obese rats.

Main Results:

• TAK-875 demonstrated a concentration-dependent inhibition of beta-cell apoptosis and improved insulin secretion in vitro.
• TAK-875 reduced TLR4 and NF-κB subunit P65 expression, with effects enhanced by TLR4 silencing and attenuated by TLR4 overexpression.
• In obese rats, TAK-875 decreased body weight, inflammatory factors, and islet cell apoptosis, while rebalancing alpha and beta-cell distribution. TLR4 knockout further protected against diet-induced damage and synergized with TAK-875.

Conclusions:

• GPR40 agonists, exemplified by TAK-875, counteract lipotoxicity-induced beta-cell damage.
• The protective mechanism involves the inhibition of the TLR4-NF-κB inflammatory pathway.
• These findings highlight GPR40 agonists as potential therapeutic agents for metabolic inflammatory damage in beta-cells.